Ribosomal protein S6 is hyperactivated and differentially phosphorylated in epidermal lesions of patients with psoriasis and atopic dermatitis

British Journal of Dermatology

Volumn 171, Issue 6, 2014, Pages 1533-1536

  Ruf, M T ^a,b   Andreoli, A ^a,b   Itin, P ^c   Pluschke, G ^a,b   Schmid, P ^a,b  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN S6;

ARTICLE; ATOPIC DERMATITIS; BASAL CELL; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KERATINOCYTE; PROTEIN PHOSPHORYLATION; PSORIASIS; SKIN DEFECT; CASE CONTROL STUDY; EPIDERMIS; FLUORESCENT ANTIBODY TECHNIQUE; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY;

CASE-CONTROL STUDIES; DERMATITIS, ATOPIC; EPIDERMIS; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; PHOSPHORYLATION; PSORIASIS; RIBOSOMAL PROTEIN S6;

EID: 84919461975     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.13248     Document Type: Article

References (15)

1. Meyuhas O,. Physiological roles of ribosomal protein S6: one of its kind. Int Rev Cell Mol Biol 2008; 268: 1-37.
2. Ferrari S, Bandi HR, Hofsteenge J, et al,. Mitogen-activated 70K S6 kinase. Identification of in vitro 40 S ribosomal S6 phosphorylation sites. J Biol Chem 1991; 266: 22770-5.
3. Wettenhall RE, Erikson E, Maller JL,. Ordered multisite phosphorylation of Xenopus ribosomal protein S6 by S6 kinase II. J Biol Chem 1992; 267: 9021-7.
4. Chung J, Kuo CJ, Crabtree GR, et al,. Rapamycin-FKBP specifically blocks growth-dependent activation of and signalling by the 70 kd S6 protein kinases. Cell 1992; 69: 1227-36.
5. Roux PP, Shahbazian D, Vu H, et al,. RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation. J Biol Chem 2007; 282: 14056-64.
6. Hutchinson JA, Shanware NP, Chang H, et al,. Regulation of ribosomal protein S6 phosphorylation by casein kinase 1 and protein phosphatase 1. J Biol Chem 2011; 286: 8688-96.
7. Frigerio E, Colombo MD, Franchi C, et al,. Severe psoriasis treated with a new macrolide: everolimus. Br J Dermatol 2007; 156: 372-4.
8. Ormerod AD, Shah SA, Copeland P, et al,. Treatment of psoriasis with topical sirolimus: preclinical development and a randomized, double-blind trial. Br J Dermatol 2005; 152: 758-64.
9. Buerger C, Malisiewicz B, Eiser A, et al,. Mammalian target of rapamycin and its downstream signalling components are activated in psoriatic skin. Br J Dermatol 2013; 169: 156-9.
10. Johansen C, Kragballe K, Westergaard M, et al,. The mitogen-activated protein kinases p38 and ERK1/2 are increased in lesional psoriatic skin. Br J Dermatol 2005; 152: 37-42.
11. Wang S, Uchi H, Hayashida S, et al,. Differential expression of phosphorylated extracellular signal-regulated kinase 1,2 phosphorylated p38 mitogen-activated protein kinase and nuclear factor-kappaB p105/p50 in chronic inflammatory skin diseases. J Dermatol 2009; 36: 534-40.
12. Sawyers CL,. Will mTOR inhibitors make it as cancer drugs? Cancer Cell 2003; 4: 343-8.
13. Sadagurski M, Yakar S, Weingarten G, et al,. Insulin-like growth factor 1 receptor signaling regulates skin development and inhibits skin keratinocyte differentiation. Mol Cell Biol 2006; 26: 2675-87.
14. El-Komy M, Amin I, Zidan A, et al,. Insulin-like growth factor-1 in psoriatic plaques treated with PUVA and methotrexate. J Eur Acad Dermatol Venereol 2011; 25: 1288-94.
15. Carr TD, DiGiovanni J, Lynch CJ, et al,. Inhibition of mTOR suppresses UVB-induced keratinocyte proliferation and survival. Cancer Prev Res 2012; 5: 1394-404.